RENATO SANZ DEL FIERRO, M.D.; ELMER L. SEVRINGHAUS, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The report by MacBryde and Roberts1 concerning the clinical use of a new type of modified protamine zinc insulin in the treatment of diabetic patients with excellent results moved us to use it in clinical trial in a small number of selected cases.
It is well known that for the great majority of diabetics, crystalline zinc insulin if divided in proper doses, or commercial protamine zinc insulin (PZI) with convenient shifts of carbohydrate allotments in the diet, will suffice. There are, however, a certain number of patients that cannot be controlled by this means, especially when they require large doses
DEL FIERRO RS, SEVRINGHAUS EL. CLINICAL USE OF NEW TYPES OF MODIFIED PROTAMINE ZINC INSULIN*. Ann Intern Med. 1945;22:667–670. doi: https://doi.org/10.7326/0003-4819-22-5-667
Download citation file:
Published: Ann Intern Med. 1945;22(5):667-670.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Hospital Medicine.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use